Ameritas Investment Partners’s Avalo Therapeutics AVTX Stock Holding History

Ameritas Investment Partners’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	-$1K	–	3075
2022 Q1	$1K	Hold	1	–	–	﹤0.01%	3060
2021 Q4	$3K	Hold	1	–	–	﹤0.01%	3072
2021 Q3	$4K	Hold	1	–	–	﹤0.01%	3041
2021 Q2	$6K	Hold	1	–	–	﹤0.01%	2981
2021 Q1	$6K	Hold	1	–	–	﹤0.01%	2971
2020 Q4	$5K	Hold	1	–	–	﹤0.01%	2963
2020 Q3	$4K	Hold	1	–	–	﹤0.01%	2999
2020 Q2	$5K	Hold	1	–	–	﹤0.01%	2945
2020 Q1	$5K	Hold	1	–	–	﹤0.01%	2802
2019 Q4	$10K	Hold	1	–	–	﹤0.01%	2730
2019 Q3	$6K	Hold	1	–	–	﹤0.01%	2882
2019 Q2	$10K	Buy	+1	New	+$15.2K	﹤0.01%	2792

Other funds holding AVTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameritas Investment Partners's AVTX Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Avalo Therapeutics (AVTX) in Q2 2022, closing a stake of 1 share — an estimated $1K sold.

Ameritas Investment Partners first reported a position in AVTX in Q2 2019 and held it in 12 quarters. The position peaked at $10K in Q4 2019. 43 funds tracked by Wall St. Rank hold AVTX as of Q2 2022.

Ameritas Investment Partners reported no remaining Avalo Therapeutics position as of Q2 2022 after selling out during the quarter.
Ameritas Investment Partners sold 1 Avalo Therapeutics share in Q2 2022, an estimated $1K.
Ameritas Investment Partners first reported a position in Avalo Therapeutics in Q2 2019 and held it in 12 quarters.
Ameritas Investment Partners's Avalo Therapeutics position peaked at $10K in Q4 2019.
43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.